Food-allergen specific antibody compositions

Patent metadata

Field	Value
Publication number	US-12188945-B2
Application number	US-202318497432-A
Country	US
Kind code	B2
Filing date	Oct 30, 2023
Priority date	Jan 31, 2017
Publication date	Jan 7, 2025
Grant date	Jan 7, 2025

Abstract

The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

First claim

What is claimed is:

1. A pharmaceutical composition comprising:
a therapeutically effective amount of an antibody or a fragment thereof, wherein the antibody or the fragment thereof binds a food allergen, wherein the food allergen is a peanut allergen and the antibody or the fragment thereof comprises heavy chain CDR1 SEQ ID NO: 105, heavy chain CDR2 SEQ ID NO: 106, heavy chain CDR3 SEQ ID NO: 107, light chain CDR1 SEQ ID NO: 183, light chain CDR2 of sequence KAS and light chain CDR3 SEQ ID NO: 185; and
a pharmaceutically acceptable carrier.

2. The composition of claim 1 , wherein the antibody or the fragment thereof is a human IgE mAb with specificity to a food allergen.

3. The composition of claim 1 , wherein the antibody or the fragment thereof is a human IgE mAb and binds to an Ara h 2 allergen or an Ara h 6 allergen from a peanut protein.

4. The composition of claim 1 , wherein the antibody or the fragment thereof comprises heavy and light chain variable sequences having 70%, 80% or 90% identity to clone paired heavy and light chain variable sequences as set forth in SEQ ID NO: 53 and SEQ ID NO: 54.

5. The composition of claim 1 , wherein the antibody or the fragment thereof comprises clone paired heavy and light chain variable sequences as set forth in SEQ ID NO: 53 and SEQ ID NO: 54.

6. The composition of claim 1 , wherein the antibody or the fragment thereof comprises paired heavy and light chain variable regions encoded by nucleic acids having at least 70% identity to the sequences as set forth in SEQ ID NO: 1 and SEQ ID NO: 2.

7. The composition of claim 1 , wherein the antibody or the fragment thereof comprises a recombinant single chain fragment variable (scFv) antibody, an Fab fragment, an F(ab′)2 fragment, or an Fv fragment.

8. The composition of claim 1 , wherein the antibody or the fragment thereof comprises an IgE, or is an IgG comprising grafted IgE CDRs or variable regions.

9. The composition of claim 1 , wherein the antibody or the fragment thereof further comprises a cell penetrating peptide.

Assignees

• Univ Vanderbilt

Inventors

• Smith Scott A

Classifications

• G01N2333/43582

  from mites · CPC title

• G01N2333/43526

  from worms · CPC title

• G01N33/5308 Primary

  for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K16/18

  against material from animals or humans · CPC title